Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, October 5th.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $8.00 to $15.00 in a research report on Wednesday, July 26th. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. BidaskClub raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price objective (up from $12.00) on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $12.96.
Tetraphase Pharmaceuticals (TTPH) traded down 0.90% during mid-day trading on Thursday, reaching $6.58. The company’s stock had a trading volume of 77,534 shares. The stock’s market capitalization is $335.93 million. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The firm has a 50-day moving average of $6.97 and a 200-day moving average of $7.24.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. During the same period last year, the company posted ($0.47) EPS. The business’s revenue was up 28.2% on a year-over-year basis. On average, equities research analysts expect that Tetraphase Pharmaceuticals will post ($2.85) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Rating Lowered by Zacks Investment Research” was first published by BBNS and is owned by of BBNS. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://baseballnewssource.com/markets/tetraphase-pharmaceuticals-inc-ttph-downgraded-by-zacks-investment-research/1699224.html.
In other news, insider Jacques Dumas sold 17,500 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the sale, the insider now owns 17,500 shares in the company, valued at $105,000. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.50% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC raised its holdings in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,496 shares during the last quarter. UBS Group AG increased its holdings in Tetraphase Pharmaceuticals by 2.3% during the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares during the last quarter. AXA purchased a new stake in Tetraphase Pharmaceuticals during the second quarter worth about $132,000. Jane Street Group LLC purchased a new stake in Tetraphase Pharmaceuticals during the first quarter worth about $181,000. Finally, Voya Investment Management LLC increased its holdings in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares during the last quarter. Institutional investors own 41.73% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.